Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

Paul, C.; Clay Cather, Jennifer; Gooderham, Melinda; Poulin, Yves; Mrowietz, Ulrich; Ferrandiz, C.; Crowley, J.; Hu, ChiaChi; Stevens, R.M.; N. Shah, Kara; M. Day, R.; Girolomoni, Giampiero; Gottlieb, A.B.

doi:10.1111/bjd.14164

Public

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

Published in British Journal of Dermatology • Sep 11, 2015

Authors:

C. Paul

Jennifer Clay Cather

Melinda Gooderham

Abstract

BACKGROUND: Apremilast, an oral phosphodiesterase 4 inhibitor, regulates immune responses associated with psoriasis. OBJECTIVES: ESTEEM 2 evaluated the efficacy and safety of apremilast 30 mg twice daily for moderate-to-severe plaque psoriasis. METHODS: This phase III, double-blind, placebo-controll...

Subject

Apremilast

Medicine

Psoriasis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!